- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Telefonnummer: 044 2836 9537
- E-Mail: bhavani.pk@icmr.gov.in
Studieren Sie die Kontaktsicherung
- Name: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Telefonnummer: 044 2836 9518
- E-Mail: narendra.ng@icmr.gov.in
Studienorte
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, Indien, 522503
- Rekrutierung
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Kontakt:
- Dr S Sathiyanarayanan, MBBS., MD
- Telefonnummer: 08645 280021
- E-Mail: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, Indien, 781101
- Aktiv, nicht rekrutierend
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, Indien, 360001
- Noch keine Rekrutierung
- Govt. PDU Medical College
-
Kontakt:
- Dr Bhoomika Patel, MBBS., MD
- Telefonnummer: 0281 245 8337
- E-Mail: doctorbhoomika@gmail.com
-
Surat, Gujarat, Indien, 395001
- Aktiv, nicht rekrutierend
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400008
- Rekrutierung
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Kontakt:
- Dr Priti Meshram, MBBS., MD., DNB
- Telefonnummer: 022 2373 5555
- E-Mail: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, Indien
- Noch keine Rekrutierung
- All India Institute Of Medical Sciences, Nagpur
-
Kontakt:
- Dr Yogesh Bahurupi, MBBS., MD
- Telefonnummer: 0712 2352078
- E-Mail: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, Indien, 793018
- Rekrutierung
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Kontakt:
- Dr Monaliza Lyngdoh, MBBS., MD
- Telefonnummer: 0364 2538013
- E-Mail: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indien, 110030
- Noch keine Rekrutierung
- National Institute of TB and Respiratory Diseases
-
Kontakt:
- Dr Jitendra Kumar Saini, MBBS., MD
- Telefonnummer: 011 2651 3325
- E-Mail: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, Indien, 751019
- Aktiv, nicht rekrutierend
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, Indien, 751001
- Aktiv, nicht rekrutierend
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indien, 600031
- Rekrutierung
- ICMR - National Institute for Research in Tuberculosis
-
Kontakt:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Telefonnummer: 044 2836 9537
- E-Mail: bhavani.pk@icmr.gov.in
-
Kontakt:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Telefonnummer: 044 2836 9518
- E-Mail: narendra.ng@icmr.gov.in
-
Hauptermittler:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Hauptermittler:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Unterermittler:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500038
- Rekrutierung
- Govt. General and Chest Hospital, Osmania Medical College
-
Kontakt:
- Dr V Karthik, MBBS., MD
- Telefonnummer: 04083814421
- E-Mail: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, Indien, 282002
- Rekrutierung
- Sarojini Naidu Medical College
-
Kontakt:
- Dr Gajendra Vikram Singh, MBBS., MD
- Telefonnummer: 0562 2260353
- E-Mail: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, Indien, 211002
- Rekrutierung
- Moti Lal Nehru Medical College
-
Kontakt:
- Dr Amitabh Das Shukla, MBBS., MD
- Telefonnummer: 0532 261 3592
- E-Mail: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, Indien, 226003
- Rekrutierung
- King George Medical University
-
Kontakt:
- Dr Rajiv Garg, MBBS., MD
- Telefonnummer: 0522 2255167
- E-Mail: rajivkgmc@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Aktiver Komparator: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Zeitfenster: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Zeitfenster: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Zeitfenster: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Zeitfenster: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Zeitfenster: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Zeitfenster: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Hauptermittler: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Infektionen der Atemwege
- Infektionen
- Erkrankungen der Atemwege
- Lungenkrankheit
- Grampositive bakterielle Infektionen
- Bakterielle Infektionen
- Bakterielle Infektionen und Mykosen
- Actinomycetales-Infektionen
- Mycobacterium-Infektionen
- Tuberkulose
- Tuberkulose, Lungen
- Qualität, Zugang und Bewertung im Gesundheitswesen
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Therapeutika
- Gesundheitsbewertungsmechanismen
- Qualität der Gesundheitsversorgung
- Polycyclische Verbindungen
- Heterocyclische Verbindungen, 4 oder mehr Ringe
- Rifamycins
- Lactams, makrocyclisch
- Makrocyclische Verbindungen
- Fluorchinolone
- 4-Quinolone
- Chinolone
- Chinoline
- Ofloxacin
- Epidemiologische Studienmerkmale
- Rifampin
- Levofloxacin
- Klinische Protokolle
Andere Studien-ID-Nummern
- 2025 011
- CTRI/2026/02/102698 (Registrierungskennung: CLINICAL TRIALS REGISTRY - INDIA)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .